Standard & Poor’s Global Ratings last week said it believes that recent payment cuts to not-for-profit hospitals under the 340B drug savings program “will likely weaken their operating performance at a time of already tightening margins.” The report notes that the cuts “could lead to negative rating actions if hospital-specific funding reductions were material and not offset by other management actions. And despite the possibility of a legal challenge to the cuts, additional proposed program reforms at the federal level could further negatively affect these providers' finances.” A federal appeals court earlier this month heard oral arguments in a case brought by the AHA, Association of American Medical Colleges, America’s Essential Hospitals and three hospital organizations to challenge a nearly 30% reduction to Medicare payments for 340B drugs. The AHA hopes for a ruling from the court sometime this summer.

Related News Articles

Headline
As urged by the AHA, the Health Resources and Services Administration today announced that it expects to publish online by April 1 drug ceiling prices under…
Headline
The Department of Health and Human Services today issued a final rule making Jan. 1 the effective date of its final regulations on drug ceiling prices and…
Blog
As the industry “that generates higher profit margins than any other,” Big Pharma continues to price gouge consumers for life-saving drugs. One thing the…
Headline
The AHA today urged the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling…
Headline
A federal court today denied the Department of Health and Human Services’ motion for a stay in a lawsuit challenging the excessive delay in the effective date…
Headline
The Centers for Medicare…